SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Biotechs >

Vericel Corp. (VCEL)

Add VCEL Price Alert      Hide Sticky   Hide Intro
Moderator: hurley cruppers, lasers
Search This Board: 
Last Post: 3/28/2017 8:11:07 AM - Followers: 153 - Board type: Free - Posts Today: 1

Vericel Corporation. (VCEL)




Acquisition of Sanofi’s CTRM Business
On May 30, 2014, we completed the acquisition of the Cell Therapy and Regenerative Medicine (CTRM) business of Sanofi, a French  société anonyme  (Sanofi), certain assets, including all of the outstanding equity interests of Genzyme Biosurgery ApS (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and over 250 patents and patent applications of Sanofi and certain of its subsidiaries, and assumed certain liabilities for purposes of acquiring the portion of the CTRM business, which researches, develops, manufactures, markets and sells Carticel, MACI and Epicel.
We believe that our acquired CTRM business has been a pioneer in the development and commercialization of autologous cell therapies. The CTRM portfolio includes three autologous cell therapy products: Carticel (autologous cultured chondrocytes), a first-generation product for autologous chondrocyte implantation (ACI) currently marketed in the U.S., Epicel (cultured epidermal autografts), a permanent skin replacement for full thickness burns in adults and pediatrics with greater than or equal to 30% of TBSA, also currently marketed in the U.S, and MACI (matrix-applied characterized autologous cultured chondrocytes), a third-generation ACI product approved in Europe and for which a Biologics License Application (BLA) is under review by the FDA. Our product candidate portfolio also includes ixmyelocel-T, a patient-specific multicellular therapy currently in development for the treatment of advanced heart failure due to ischemic DCM.




                                                                      Click on Yellow to REVIEW FDA WEBSITE APPROVING MACI


Interesting FDA Transcript discussions on MACI going forward for widened age bracket and other body joints. 
                                                                                                                                      CLICK ON THE ABOVE LINK



 Our preapproval stage portfolio includes ixmyelocel-T, a unique patient-specific multicellular therapy derived from an adult patient’s own bone marrow which utilizes our proprietary, highly automated and scalable manufacturing system. Our proprietary cell manufacturing process significantly expands the mesenchymal stromal cells (MSCs) and M2-like anti-inflammatory macrophages in the patient’s bone marrow mononuclear cells while retaining many of the hematopoietic cells. These cell types are known to regulate the immune response and play a key role in tissue repair and regeneration by resolving pathologic inflammation, promoting angiogenesis, and remodeling ischemic tissue. The novelty and advantage of using ixmyelocel-T is the expansion of a unique combination of cell populations, including MSCs and M2-like macrophages, which secrete a distinct combination of angiogenic and regenerative factors, and possess the ability to remain anti-inflammatory in the face of inflammatory challenge.

Our lead clinical development program for ixmyelocel-T is focused on severe, chronic ischemic cardiovascular diseases. We have completed the double-blind portion of the Phase 2b ixCELL-DCM study, which is a randomized, double-blind, placebo-controlled clinical trial for patients with advanced heart failure due to ischemic DCM. Ixmyelocel-T has been granted a U.S. Orphan Drug designation by the FDA for the treatment of DCM. We also have conducted clinical studies for the treatment of critical limb ischemia and the treatment of craniofacial defects.
The Phase 2b ixCELL-DCM clinical study treated 114 patients at 28 sites in the U.S. and Canada. We completed enrolling and treating patients in February, 2015. Patients were followed for 12 months for the primary efficacy endpoint of major adverse cardiovascular events, defined as all-cause deaths, all-cause hospitalizations, and unplanned outpatient or emergency department visits for IV treatment of acute worsening heart failure. Secondary endpoints include clinical, functional, structural, symptomatic, quality of life, and biomarker measures at 3, 6 and 9 months. On March 10, 2016, we announced the trial had met its primary endpoint of reduction in clinical cardiac events, and that the full data results from the ixCELL-DCM trial were presented at the Late-Breaking Clinical Trial Sessions of the American College of Cardiology 65 th Annual Scientific Session & Expo on April 4, 2016. On April 4, 2016, we announced that incidence of adverse events, including serious adverse events, in patients treated with ixmyelocel-T was comparable to or lower than patients in the placebo group.  With respect to the secondary endpoints of the trial, the components of the primary endpoint were also analyzed using the Win ratio in a hierarchical manner to incorporate both the incidence and timing of the endpoint components.  The Win ratio result of 1.56 showed that more often ixmyelocel-T was the "winner" in that the time to death, left ventricular assist device placement, heart transplantation or time to cardiovascular hospitalization was shorter for placebo-treated patients, but this difference did not reach statistical significance.  The time to first

Table of Contents
event was longer in the ixmyelocel-T group compared to placebo, but was not statistically significant.  There were no significant structural changes in left ventricle cavity size or left ventricular ejection fraction as measured by echocardiogram in either the ixmyelocel-T or placebo groups.  Both treatment groups had an improvement in the New York Heart Association class and six-minute walk test, with no statistical difference between the groups after 12 months using the last observation carried forward. Because the trial met the primary endpoint, patients who had been assigned to the placebo group or randomized to ixmyelocel-T in the double blind portion of the trial but did not receive ixmyelocel-T will be offered the option to receive treatment.
Future development plans for ixmyelocel-T are dependent upon input from our regulatory interactions and the availability of financing. We are focused on determining the most appropriate manner to fund future development of ixmyelocel-T, balancing risk to the overall business, dilution to current shareholders, and retaining a significant portion of the upside potential of the program for the company and our shareholders.

Ixmyelocel-T for Craniofacial Tissue Engineering

                           Click on above picture to enter another talk/idea zone


About Vericel Corporation:

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant intended to treat cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.  Vericel is also developing 2 additional cell products. MACI is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM).

Developing autologous (patient’s own) cell therapies—with integrity
Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient’s own) cells.  In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work.  We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.

                                                                                               CLICK ON ABOVE PICTURE TO SEE NASDAQ.COM SHORT INTEREST

Clinical Research:
Recent News:

Events and Presentations:

Analyst Coverage:


Share Structure:
See Filings

YOU TUBE VIDEOS, and the fourth video down, you will NOW appreciate the meaning of less invasive on the new FDA approved MACI procedure and why MACI is anticipated to be 20x the procedures of Carticel  MUST WATCH

Conference Calls
September 27, 2016 Ladenburg Thalmann
October 24, 2016 Meeting on the Mesa
November 30th, 2016 The 28th Annual Piper Jaffray Healthcare Conference
December 14th, 2016 Vericel Corporation Investor Call

Investor Relations:




 Yummy Land, click on Above Picture


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
News News Alert: Vericel to Present at the 16th Annual Needham Healthcare Conference 03/28/2017 08:00:00 AM
#5647  Sticky Note $VCEL Daily and Weekly Charts http://www.stock $Pistol Pete$ 02/01/17 12:40:12 PM
#4674  Sticky Note The ixCELL-DCM Trial: Transendocardial Injection of ixmyelocel-T in lasers 04/05/16 05:33:01 PM
#6077   Vericel Corporation (Nasdaq:VCEL), a leading developer of expanded realfast95 03/28/17 08:11:07 AM
#6076   general market malaise not unusual in the few gamesetmatch101 03/27/17 02:56:11 PM
#6075   If everyone who owns VCEL, bought an additional Gremlin3a 03/26/17 10:29:18 PM
#6074   If investors felt more secure with the growth Rubyt 03/26/17 09:32:24 PM
#6073   " I don't understand why the PPS is commoncentsinvestor 03/26/17 09:23:11 PM
#6072   How low can this go? This should be Rubyt 03/26/17 08:31:24 PM
#6071   what is status of work in cancer vaccine gamesetmatch101 03/26/17 10:12:36 AM
#6070   Since mid January, short interest is up 65% commoncentsinvestor 03/25/17 11:30:51 PM
#6069   Until either they all get wiped out overnight me33 03/25/17 10:23:21 AM
#6068   Looks like shorts are still at it, as Gremlin3a 03/25/17 10:01:30 AM
#6067   Can someone ask VCEL if Epicel can be hurley cruppers 03/24/17 11:17:19 PM
#6066 renovacare OTC RCAR realfast95 03/24/17 10:18:41 AM
#6065   Here's another from 2014- scubastevemd 03/24/17 08:54:49 AM
#6064   Not sure what has happened to this concept scubastevemd 03/24/17 08:52:25 AM
#6063   Completely agree with everything you said. commoncentsinvestor 03/23/17 10:26:37 PM
#6062   Session C-009 - Reconstruction lasers 03/23/17 12:24:13 PM
#6061   That .05 spread doesn't help (longs) either imo. Sugarplum 03/23/17 11:28:04 AM
#6060   Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded realfast95 03/23/17 10:22:59 AM
#6059   Exactly and excellent post. $VCEL products are direct lasers 03/23/17 05:28:20 AM
#6058   Because VCEL is currently under a short attack commoncentsinvestor 03/23/17 12:55:31 AM
#6057   no kidding. TVDirector 03/22/17 03:08:45 PM
#6056   I only hope when FDA approves YXMIELOCEL in manisero66 03/20/17 01:14:25 PM
#6055   Great DD realfast95 hurley cruppers 03/18/17 09:00:23 PM
#6054   Finally, Dr. Christian Lattermann University of KY, is realfast95 03/18/17 02:28:26 PM
#6053   Takeda, Janssen and Vericel Corporation Discuss Rapid Microbial realfast95 03/17/17 06:02:12 AM
#6052   HSGX fixed their math problem. They filed a realfast95 03/17/17 05:54:17 AM
#6051   It is definitely not any competition to VCEL hurley cruppers 03/16/17 11:36:50 PM
#6050   HSGX should be a firm candidate for delisting. manisero66 03/16/17 07:19:11 PM
#6049   HSGX "We enrolled 82 patients in the NeoCart Phase realfast95 03/16/17 06:52:34 AM
#6048   HSGX commoncentsinvestor 03/15/17 06:21:13 PM
#6047   Vericel (VCEL) Presents At Canaccord Genuity2017 Musculoskeletal Conference lasers 03/15/17 06:19:57 PM
#6046   VCEL's only competition was also presenting at these realfast95 03/15/17 01:01:40 PM
#6045 lasers 03/15/17 12:32:18 PM
#6044   veeets welcome. lasers 03/14/17 10:42:48 AM
#6043   When this runs it will happen quickly due veeets 03/14/17 10:21:31 AM
#6042   Based on company statement 2017 is $44K per Sugarplum 03/14/17 10:08:10 AM
#6041   I haven't see the Needham analyst report or realfast95 03/14/17 06:01:41 AM
#6040   for a minute there, I thought he wasn't realfast95 03/13/17 11:56:30 AM
#6039   Shouldn't matter because the consensus analysts views is lasers 03/13/17 08:45:40 AM
#6038   but Needham lowered the target from $9 realfast95 03/13/17 08:36:26 AM
#6037   COVERAGE REITERATED: Vericel (VCEL) reiterated by Needham. Reiterated lasers 03/13/17 08:01:46 AM
#6036   $VCEL Pre-Mkt today 3300 shs total all at $3.30 lasers 03/13/17 08:00:59 AM
#6035   I stand corrected...pre-market volume is 3300. north40000 03/13/17 07:29:31 AM
#6034   3 trades, 100,1900,1300 all at 3.30 realfast95 03/13/17 07:06:08 AM
#6033   VCEL: saw 1 PM trade on CNBC scroll north40000 03/13/17 07:00:38 AM
#6032   VCEL Upcoming Events - Tomorrow morning 8am Roth hurley cruppers 03/12/17 08:07:52 PM
#6031   $VCEL expanding globally lasers 03/12/17 06:42:54 PM
#6030   That will bring the sales territories to 28. lasers 03/12/17 06:35:16 PM
#6029   I see there are only 2 sales jobs hurley cruppers 03/12/17 06:27:10 PM
#6028   Dr. Scott Gottlieb will be making those decisions lasers 03/12/17 06:22:57 PM